Ligand Pharmaceuticals Inc. has followed its sale of Avinza rights for $265 million to King Pharmaceuticals Inc. by offloading three more drugs - the rest of the firm's commercial operations - to Eisai Co. Ltd. for $205 million plus royalties, in what Ligand called an ongoing "shareholder value maximization process." (BioWorld Today)